Part,  Chapter, Paragraph

  1    I,     2.  5.  0(3) |             CAT_PREREL_YEAR_2008_MONTH_12/2-16122008-EN-AP.PDF~
  2    I,     2. 10.  4    |      transcription account for 11% and 12%. While about half of the
  3    I,     2. 11        |                Perspectives, 115(1), 5-12~Suhrcke M, McKee M, Sauto
  4    I,     3.  1        |                the United Kingdom, and 12-13% in Italy and the Netherlands;
  5    I,     3.  2        |             high natural increase. The 12 new Member States have a
  6    I,     3.  3        |            show that the trends in the 12 new Member States are fluctuating
  7   II,     4.  1        |         duration is much larger in the 12 new Member States (8 years)
  8   II,     4.  2        |              causes (causes 10, 11 and 12 in table 3) has decreased
  9   II,     4.  2        |             countries and for women in 12 countries, even though for
 10   II,     4.  2        |           impact on life expectancy in 12 of the 13 countries. In
 11   II,     5.  2.  5    |             was officially launched on 12 June 2007 before the European
 12   II,     5.  2.  7    |               2006 [htt ] (accessed on 12.07.07).~EUROCISS Working
 13   II,     5.  2.  7    |           EUROSTAT [htt ] (accessed on 12.07.07).~Evans A, Tolonen
 14   II,     5.  2.  7    |             women and men: findings on 12 Italian population samples.
 15   II,     5.  2.  7    |             HFA-DB [htt ] (accessed on 12.07.07).~WHO MONICA Project [
 16   II,     5.  2.  7    |               fi/monica/] (accessed on 12.07.07).~WHO Regional Office
 17   II,     5.  3.  5    |              and in Estonia for women (12 deaths per 100,000). Incidence
 18   II,     5.  3.  6    |                   lung (European mean: 12%), breast (European mean:
 19   II,     5.  3.  9    |           Health Strategies in Europe, 1213 July 2007, Strategies
 20   II,     5.  3.  9    |           Health Strategies in Europe, 1213 July 2007, Strategies
 21   II,     5.  4.  2    |              000 population 014 years~12~HES/HIS Registry~Prevalence
 22   II,     5.  4.  2    |             100,000 general population~12~National Registry~Annual
 23   II,     5.  4.  2    |           European Standard Population~12~National Registry~Acronyms:~
 24   II,     5.  4.  2    |             and a HbA1c tested in last 12 months~16~Percent of diabetic
 25   II,     5.  4.  2    |              lipid profile in the last 12 months~14~Percent of diabetic
 26   II,     5.  4.  2    |            subjects tested in the last 12 months with total cholesterol>
 27   II,     5.  4.  2    |            subjects tested in the last 12 months with LDL>2.6 mmol/
 28   II,     5.  4.  2    |            subjects tested in the last 12 months with HDL<1.15 mmol/
 29   II,     5.  4.  2    |            subjects tested in the last 12 months with triglycerides >
 30   II,     5.  4.  2    |               2.3 mmol/l (>2.0 mmol/l)~12~Percent of diabetic subjects
 31   II,     5.  4.  2    |           microalbuminuria in the last 12 months~12~Percent of diabetic
 32   II,     5.  4.  2    | microalbuminuria in the last 12 months~12~Percent of diabetic subjects
 33   II,     5.  4.  2    |           microalbuminuria in the last 12 months, with an abnormal
 34   II,     5.  4.  2    |           pressure measurement in last 12 months~14~Percent of of
 35   II,     5.  4.  2    |             blood pressure in the last 12 months showing a value >
 36   II,     5.  4.  2    |          fundus inspection in the last 12 months~11~Percent of diabetic
 37   II,     5.  4.  2    |            subjects tested in the last 12 months, with proliferative
 38   II,     5.  4.  2    |      proliferative retinopathy in last 12 months~6~Percent of diabetic
 39   II,     5.  4.  2    |               serum creatinine in last 12 months~13~Percent of diabetic
 40   II,     5.  4.  2    |        haemoglobin (HbA1c) in the last 12 months is measured as the
 41   II,     5.  4.  2    |             HbA1c measured in the last 12 months. EUCID results were
 42   II,     5.  4.  2    |                cholesterol in the last 12 months is an important parameter
 43   II,     5.  4.  2    |         cholesterol tested in the last 12 months.~Total cholesterol
 44   II,     5.  4.  2    |             cholesterol tested in last 12 months showing a total cholesterol
 45   II,     5.  4.  2    |                cholesterol in the last 12 months is another important
 46   II,     5.  4.  2    |     LDL-cholesterol tested in the last 12 months.~LDL cholesterol
 47   II,     5.  4.  2    |     LDL-cholesterol tested in the last 12 months and presenting a
 48   II,     5.  4.  2    |                cholesterol in the last 12 months is also taken as
 49   II,     5.  4.  2    |     LDL-cholesterol tested in the last 12 months.~HDL cholesterol
 50   II,     5.  4.  2    |     HDL-cholesterol tested in the last 12 months and HDL cholesterol
 51   II,     5.  4.  2    |              triglycerides in the last 12 months is the last important
 52   II,     5.  4.  2    |       triglycerides tested in the last 12 months.~Triglycerides level >
 53   II,     5.  4.  2    |             cholesterol tested in last 12 months showing a total cholesterol
 54   II,     5.  4.  2    |        proteinuria exists) in the last 12 months.~An abnormal level
 55   II,     5.  4.  2    |             proteinuria tested in last 12 months with a microalbuminuria
 56   II,     5.  4.  2    |          pressure measured in the last 12 months. The median is 95%
 57   II,     5.  4.  2    |          pressure measured in the last 12 months and reported a diastolic
 58   II,     5.  4.  2    |               fundus inspected in last 12 months. This indicator is
 59   II,     5.  4.  2    |           fundus inspected in the last 12 months and were diagnosed
 60   II,     5.  4.  2    |           fundus inspected in the last 12 months and were diagnosed
 61   II,     5.  4.  2    |      creatinine tested during the last 12 months.~Renal failure is
 62   II,     5.  4.  2    |          creatinine tested in the last 12 months and End Stage Renal
 63   II,     5.  4.  3    |              Poland (15%) and Denmark (12%) showing the highest values.
 64   II,     5.  4.  3    |        haemoglobin (HbA1c) in the last 12 months. OECD data (Armesto
 65   II,     5.  4.  3    |                cholesterol in the last 12 months. EUCID crude data
 66   II,     5.  4.  3    |          months. EUCID crude data from 12 countries are consistent
 67   II,     5.  4.  3    |                cholesterol in the last 12 months. The EUCID indicator
 68   II,     5.  4.  3    |                cholesterol in the last 12 months. The EUCID indicator
 69   II,     5.  4.  3    |              triglycerides in the last 12 months. EUCID crude data
 70   II,     5.  4.  3    |                and 46% (Sweden) across 12 countries, with a median
 71   II,     5.  4.  3    |              among diabetics. In EUCID 12 countries provided data;
 72   II,     5.  4.  3    |            showing a variation between 12% (Ireland) and 84% (Netherlands).
 73   II,     5.  4.  3    |           fundus inspected in the last 12 months and were diagnosed
 74   II,     5.  4.  4    |               in Europe ranges between 12% (Netherlands) and 25% (
 75   II,     5.  4.  8    |         mellitus, Diabet Med. 1995 Mar;12(3):271-6~Beck, P, Battlogg,
 76   II,     5.  5.Int(21)|               and of the Council of 22.12.1998, Official Journal L26/
 77   II,     5.  5.  1    |                1 presents lifetime and 12 month prevalence rates (%)
 78   II,     5.  5.  1    |             Table 5.5.1.1 Lifetime and 12 month prevalence of mood
 79   II,     5.  5.  1    |              no mental disorder during 12 months, ESEMeD Study.~ ~
 80   II,     5.  5.  1    |          variations over approximately 12 years is given in Table
 81   II,     5.  5.  2    |   International (ADI). For this study, 12 international experts conducted
 82   II,     5.  5.  3    |               increases with age: from 12% for 11-year-olds to 23%
 83   II,     5.  5.  3    |    dissatisfaction increases with age: 12% for 11-year-olds, 23% for
 84   II,     5.  5.  3    |            article online, accessed on 12 March 2007).~The Cleveland
 85   II,     5.  5.  3    |            article online, accessed on 12 March 2007).~World Health
 86   II,     5.  5.  3    |             data from Germany from the 12-months period between July
 87   II,     5.  5.  3    |                with the highest SMR of 12.86. The authors found that
 88   II,     5.  5.  3    |           seeking in these surveys was 12 months (Kohn et al, 2004).~
 89   II,     5.  5.  3    |         treatment discontinuation over 12 months in patients with
 90   II,     5.  5.  3    |          project. Qual Saf Health Care 12:18-23.~Andlin-Sobocki P,
 91   II,     5.  5.  3    |                in Europe. Eur J Neurol 12 Suppl 1:1-27.~Andlin-Sobocki
 92   II,     5.  5.  3    |                in Europe. Eur J Neurol 12 Suppl 1:74-77.~Andrews G,
 93   II,     5.  5.  3    |                       5-14 years - = 6-12 years MR = Medical record
 94   II,     5.  5.  3    |          policies~Prevalent cohorts~32~12.4~2.6~Preston and Clarke,
 95   II,     5.  5.  3    |        institution~Cross-sectional~105~12.0~8.7~Alstrom, 1942 (*)~ ~
 96   II,     5.  5.  3    |               5-year remission rate at 12-30 years of age children
 97   II,     5.  5.  3    |      Exceptions (ban)~___ __~Belgium I 12 months First unprovoked
 98   II,     5.  5.  3    |                 with driving~Denmark I 12 months Seizures during sleep (
 99   II,     5.  5.  3    |              II - Prohibited~Finland I 12 months First unprovoked
100   II,     5.  5.  3    |               II - Prohibited~France I 12 months Seizures only on
101   II,     5.  5.  3    |             previous 3 years~Germany I 12 months Single seizures or
102   II,     5.  5.  3    |       idiopathic (24 months)~Ireland I 12 months Seizures during sleep
103   II,     5.  5.  3    |               Prohibited~Netherlands I 12 months First unprovoked
104   II,     5.  5.  3    |                 activity)~ ~ ~Norway I 12 months Drugs stolen or last
105   II,     5.  5.  3    |          months (taxi) -~Switzerland I 12 months -~United Kingdom
106   II,     5.  5.  3    |              months -~United Kingdom I 12 months Seizures during sleep
107   II,     5.  5.  3    |        systematic review. Eur J Neurol 12:245-253.~Fraser RT, Clemmons
108   II,     5.  5.  3    |                Greece. Eur Neurol 49:8-12.~Poser CM, Paty DW, Scheinberg
109   II,     5.  5.  3    |               After a mean duration of 12 years, patients require
110   II,     5.  5.  3    |                 Rosati et al, 1980) to 12,500/100,000 for institutionalised
111   II,     5.  5.  3    |           variations in rates (65.6 to 12,500/100,000) may be the
112   II,     5.  5.  3    |              the highest prevalence of 12,500/100,000 was obtained
113   II,     5.  5.  3    |               productivity loss due to 12 major diseases in 6 countries
114   II,     5.  5.  3    |                in Europe. Eur J Neurol 12 Suppl 1:1-27.~Baldereschi
115   II,     5.  5.  3    |          Rotterdam Study. Neurology 45(12):2143-2146.~de Rijk MC,
116   II,     5.  5.  3    |                in Europe. Eur J Neurol 12 Suppl 1:68-73.~Logroscino
117   II,     5.  5.  3    |           atrophy. J Neural Transm 112(12):1605-1612.~von Campenhausen
118   II,     5.  6.  3    |               6 per 1000 for men and 3-12 per 1000 for women. In all
119   II,     5.  6.  4    |               common reason (Table 5.6.12). (European Commission (
120   II,     5.  6.  4    |                Conditions)~ ~Table 5.6.12. Distribution (in per cent)
121   II,     5.  6.  6    |              and women. Osteoporos Int 12:555-558~Palmer KT, Walsh
122   II,     5.  7.  3    |                ml/min per 1.74 m2 ) of 12.1 cases per million of the
123   II,     5.  7.  3    |               adults are available for 12 countries. The data for
124   II,     5.  7.  3    |                  cohort 1990-1994) and 12% (cohort 1995-1999) lower
125   II,     5.  8.  3    |               were assessed at 22% and 12% in never-smokers (Pelkonen
126   II,     5.  8.  3    |            women respectively to: mild 12.3 and 7.3%, moderate 4.5
127   II,     5.  8.  3    |                Disease (BOLD) studies (12 centres; 5 European centres)
128   II,     5.  8.  4    |                smokers, and to 22% and 12% in never-smokers (Pelkonen
129   II,     5.  8.  5    |              was 16.3%, whereas it was 12.0% in those with normal
130   II,     5.  8.  6    |                showed that in the last 12 months of life, decedents
131   II,     5.  8.  6    |             term care setting (41% vs. 12.5%, p<0.05) and to receive
132   II,     5.  8.  7    |                lung cancer in the last 12 months of life. Respir Med
133   II,     5.  9. FB    |                meta-analysis including 12 studies examined the effect
134   II,     5.  9.  3    |               2.63 and 95% CI = 2.20-3.12 for 1974-1979 vs 1953-1958
135   II,     5.  9.  3    |           Figure 5.9.1. Wheeze in last 12 months in ECHRS and ISAAC
136   II,     5.  9.  3    |              data available indicate a 12.9% of prevalence in children,
137   II,     5.  9.  3    |                in children, Czech Rep. 12.5%, Croatia 12.1%, Serbia
138   II,     5.  9.  3    |              Czech Rep. 12.5%, Croatia 12.1%, Serbia 11.6%, Iceland
139   II,     5.  9.  4    |             relative risk (RR) 1.32 (1.12, 1.56), even in those with
140   II,     5.  9.  4    |              present, RR 1.01 (0.91, 1.12) for wheeze and 1.02 (0.
141   II,     5.  9.  4    |                caused by grass pollen (12.7%), followed by house dust
142   II,     5.  9.  4    |                s diagnosis of asthma - 12.4% of the males and 8.0%
143   II,     5.  9.  4    |              et al, 2007) performed in 12 I Italian centres, showed
144   II,     5.  9.  7    |               hay fever, and eczema in 12-14 year olds in the British
145   II,     5.  9.  7    |               J Laryngol Otol. Dec;117(12):946-50.~ ~L I (2008): Tobacco smoke
146   II,     5. 10.  1    |             particular food, and about 12% declare to experience such
147   II,     5. 10.  3    |           conducted on young adults of 12 European countries plus
148   II,     5. 10.  3    |             ECRHS project estimates in 12.2% the prevalence of self-reported
149   II,     5. 10.  3    |          adults and children was about 12% (Rona et al, 2007).~ ~Figure
150   II,     5. 11.  3    |                Danish school children (12-16 yrs)~Lifetime prevalence=
151   II,     5. 11.  3    |                Danish school children (12-16 yrs)~Prevalence=15%~Mortz
152   II,     5. 11.  3    |            Danish school children aged 12-16 yrs~Point prevalence=
153   II,     5. 11.  3    |              from 24.8% to 9.2% over a 12-year period (CS Jensen et
154   II,     5. 11.  3    |               and upper limbs for SCC (12% in men and 12.5% in women) (
155   II,     5. 11.  3    |                for SCC (12% in men and 12.5% in women) (Plesko et
156   II,     5. 11.  3    |            countries (28 500 cases and 12 000 deaths) (Ferlay et al,
157   II,     5. 12        |                                      5.12. Liver cirrhosis~ ~
158   II,     5. 12.  1    |                                      5.12.1. Introduction~ ~In the
159   II,     5. 12.  2    |                                      5.12.2. Data sources~ ~ ~Official
160   II,     5. 12.  3    |                                      5.12.3. Data description and
161   II,     5. 12.  3    |             been reported in Figures 5.12.1 (A and B) and 5.12.2 (
162   II,     5. 12.  3    |         Figures 5.12.1 (A and B) and 5.12.2 (A and B).~ ~ ~ ~Table
163   II,     5. 12.  3    |                A and B).~ ~ ~ ~Table 5.12.1 gives the age-standardized
164   II,     5. 12.  3    |               in percentage.~ ~Table 5.12.1. Age-adjusted (world population)
165   II,     5. 12.  3    |                Spain had rates between 12 and 15/100,000, and Portugal
166   II,     5. 12.  3    |               8 to 20.3, Bulgaria from 12.5 to 19.4, Poland from 13.
167   II,     5. 12.  3    |            from all countries (Table 5.12.2), but trends were similar
168   II,     5. 12.  3    |              24-30/100,000).~ ~Table 5.12.2. Age-adjusted (world population)
169   II,     5. 12.  3    |         countries are given in Table 5.12.3 for men and in Table 5.
170   II,     5. 12.  3    |               3 for men and in Table 5.12.4 for women. Given the substantial
171   II,     5. 12.  3    |                from Ireland.~ ~Table 5.12.3. Joinpoint regression
172   II,     5. 12.  3    |         countries, 1970-2002~ ~Table 5.12.4. Joinpoint regression
173   II,     5. 12.  4    |                                      5.12.4. Risk factors~ ~The patterns
174   II,     5. 12.  5    |                                      5.12.5. Control tools and policies~ ~
175   II,     5. 12.  6    |                                      5.12.6. Future developments~ ~
176   II,     5. 12.  7    |                                      5.12.7. References~ ~Alter MJ,
177   II,     5. 12.  7    |              prevention. Epidemiol Rev 12:221-227.~ ~Shepard CW, Finelli
178   II,     5. 14.  1    |               out normallyage 10 to 12allows adequate dental
179   II,     5. 14.  2    |          present per children at 6 and 12 years of age.~Numerator:
180   II,     5. 14.  2    |          present per children at 6 and 12 years of age.~Denominator:
181   II,     5. 14.  2    |            number of children at 6 and 12 years of age surveyed.~ ~
182   II,     5. 14.  2    |            population in the age group 12, 15, 18 and 35-44 and 65-
183   II,     5. 14.  2    |           individuals in the age group 12, 15, 18 and 35-74 years
184   II,     5. 14.  2    |           individuals in the age group 12, 15, 18 and 35-74 years
185   II,     5. 14.  2    |           status is recommended at age 12 and 15.~ ~d. Edentulous
186   II,     5. 14.  3    |         serious decay threshold at age 12, varying around 1-1.5 score
187   II,     5. 14.  3    |           programmes for children. For 12-year-olds the United Kingdom
188   II,     5. 14.  3    |               5.14.1. Dental Health in 12 year-old children in selected
189   II,     5. 14.  3    |          management. In France, 40% of 12-year olds have no caries
190   II,     5. 14.  3    |             within European countries (12.8% in Italy, 16.3% in France,
191   II,     5. 14.  3    |                a random sample of 1379 12-year old children in Leicestershire
192   II,     5. 14.  3    |               6-year-olds and 55.6% of 12-year-olds; 17.8% of children
193   II,     5. 14.  3    |           Figure 5.14.3. Children aged 12 with a dental contact within
194   II,     5. 15.  3    |              the age of 1 and 5 and to 12.5% of deaths between 5 and
195   II,     5. 15.  6    |          Available at: htt , (accessed 12.05.2007).~ ~European Commission (
196   II,     5. 15.  6    |          Available At:~htt m (accessed 12.05.2007)~Eurordis (2005):
197   II,     5. 15.  6    |          Available at:~htt 8 (accessed 12.05.2007)~Haffner ME (2006):
198   II,     6.  3.  3    |             decreasing trend. In 2005, 12 945 syphilis cases were
199   II,     6.  3.  5    |              the EU in early 2001, and 12 European countries have
200   II,     6.  3.  6    |              000) followed by Finland (12.2 per 100 000) reporting
201   II,     6.  3.  6    |                25 countries. Latvia (2.12 per 100 000), followed by
202   II,     7.  1        |                 corresponding to about 12% of the entire European
203   II,     7.  3.  1    |                Roughly 60 million – or 12% - out of 500 million EU
204   II,     7.  3.  4    |               in Chapter 6.2. Figure 7.12. Non-fatal work place accidents
205   II,     7.  3.  4    |               working days.~ ~Figure 7.12. Non-fatal work place accidents
206   II,     7.  4.  3    |            were bicyclists. Only about 12% of cyclist injuries have
207   II,     8.  1.  3    |     considerably restricted were about 12%) in the age group 55-64.
208   II,     8.  1.  3    |             support and understanding (12%) and assistance with mobility (
209   II,     8.  1.  3    |            with strong limitations are 12% lower, while those of women
210   II,     8.  2.  2    |                 Ophtalmic Epidemiology 12:243-250.~European Union
211   II,     9            |           having got drunk in the last 12 months peaks in Denmark (
212   II,     9            |                used it in the previous 12 months. Regular use of cannabis (
213   II,     9            |               39 times in the previous 12 months) is highest (15%
214   II,     9.  1.  1    |           Gynecol Scand 2000;79(2):107-12.~ ~Huang DY, Usher RH, Kramer
215   II,     9.  1.  1    |               Med Child Neurol 2000;42(12):816-24.~ ~Stephenson PA,
216   II,     9.  1.  1    |           obstetrical interventions in 12 countries. Paediatr Perinat
217   II,     9.  1.  2    |              Diagnosis, Vol 24, pp 908-12.~Garne E et al (1999): "
218   II,     9.  2.  3    |                or more in the previous 12 months (HBSC, 2004). Unintentional
219   II,     9.  2.  3(2) |               wheezing in the previous 12-month period in 13- to 14-
220   II,     9.  2.  4    |           having got drunk in the last 12 months peaks in Denmark (
221   II,     9.  2.  4    |                used it in the previous 12 months. Regular use of cannabis (
222   II,     9.  2.  4    |               39 times in the previous 12 months) is highest (15%
223   II,     9.  2.  7    |       Birthweight. NeoReviews Vol.5 No.12 2004 e522. American Academy
224   II,     9.  2.  7    |              20drinking%22 ] (accessed 12.01.07)~ ~Ståhl T, Wismar
225   II,     9.  2.  7    |                 Copenhagen, Bucharest, 12 September 2005~ ~WHO (2006)
226   II,     9.  3.  1    |      recognized to have occurred after 12 consecutive months of amenorrhea
227   II,     9.  3.  1    |              populations have close to 12% disability. There is a
228   II,     9.  3.  1    |            serum level is > 346 ng/dL (12 nmol/L) ART is not necessary,
229   II,     9.  3.  1    |         Journal of Impotence Research. 12(6): p. 305-311.~ ~British
230   II,     9.  3.  1    |                Eurosurveillance weekly 12, on-line article available
231   II,     9.  3.  1    |           Journal of Neurology, Volume 12, Number 4, April 2005 ,
232   II,     9.  3.  1    |                Article online,accessed 12.06)~ ~International Obesity
233   II,     9.  3.  2    |           Gynecol Scand 2000;79(2):107-12.~ ~Huang DY, Usher RH, Kramer
234   II,     9.  3.  2    |           obstetrical interventions in 12 countries. Paediatr Perinat
235   II,     9.  3.  2    |               Med Child Neurol 2000;42(12):816-24.~ ~Temmerman M,
236   II,     9.  3.  3    |             coital act during the last 12 months;~· percentage of
237   II,     9.  3.  3    |             Official Journal C 271 E , 12/11/2003 P. 0369 - 0374~Facultes
238   II,     9.  4.  2    |                project, carried out in 12 European countries, was
239   II,     9.  4.  7    |          Gerontol A Biol Sci Med Sci, (12), p.1277-84.~DECODE study
240   II,     9.  5.  3    |                there were an estimated 12.9 million incidents of domestic
241   II,     9.  5.  5    |              Council Conclusions of 16.12.2005 on the implementation
242   II,     9.  5.  6    |          Available at:~htt p~(Accessed 12.07.07)~ ~Age Concern (2007b):
243   II,     9.  5.  6    |          Available at:~htt 4 (accessed 12.07.07)~ ~Cutler D, Deaton
244   II,     9.  5.  6    |              of health. Soc Sci Med 58(12):2585-2600~ ~De Smedt M, (
245   II,     9.  5.  6    |                Available at: (accessed 12.07.07)~ ~Iredale R, Reid
246   II,     9.  5.  6    |                of Women’s Studies, Vol 12(3): 377-395; SAGE Publications~ ~
247   II,     9.  5.  6    |           Biomarkers Prev. 2006 Dec;15(12):2494-501~ ~Middle C, Johnson
248   II,     9.  5.  6    |                Available at: (accessed 12.07.07)~ ~New South Wales
249   II,     9.  5.  6    |                 Copenhagen, Bucharest, 12 September 2005. Available
250   II,     9.  5.  6    |          Available at:~htt f (accessed 12.07.07)~ ~WHO: Intimate partner
251   II,     9.  5.  6    |          Available at:~htt f (accessed 12.07.07)~ ~WHO (2000): Women’
252   II,     9.  5.  6    |                Available at: (accessed 12.07.07)~ ~Women’s Health
253   II,     9.  5.  6    |                Available at: (accessed 12.07.07)~ ~
254  III,    10.  1.  3    |         interaction. Arch Dermatol 136(12):1544-6.~Szklo M, Nieto
255  III,    10.  2.  1    |        developed world, accounting for 12% of total DALYs (Lopez,
256  III,    10.  2.  1    |               health. Tobacco Control; 12:360-367~ ~Boyle P, Autier
257  III,    10.  2.  1    |               once during the previous 12 months, and 65% had consumed
258  III,    10.  2.  1    |            average during the previous 12 months Table 10.2.1.2.1.
259  III,    10.  2.  1    |              all men (31%) than women (12%) had binged at least once
260  III,    10.  2.  1    |             girls in Ireland, but only 12%-13% of boys and 5%-7% of
261  III,    10.  2.  1    |                for men, accounting for 12% of all male ill-health
262  III,    10.  2.  1    |         Related Clinical Problems 4: 512.~ ~Darke S, Kaye S (2004)
263  III,    10.  2.  1    |     Schoolchildren Between the Ages of 12 and 18 Handbook for Implementing
264  III,    10.  2.  1    |               delivery of methadone in 12 Member States of the European
265  III,    10.  2.  1    |            with fluoride toothpaste in 12 years old children~ ~· Percentage
266  III,    10.  2.  1    |               place.~ ~· Proportion of 12-year-old children according
267  III,    10.  2.  1    |  tooth-brushing frequency from Finnish 12 year olds issue from the
268  III,    10.  2.  1    |              63% and 65%) of eight and 12-year-olds and about half (
269  III,    10.  2.  1    |                observed among 5, 8 and 12 year olds. Among 15 year
270  III,    10.  2.  1    |              of children at the age of 12 had poor oral hygiene (de
271  III,    10.  2.  1    |              that almost two thirds of 12-year-olds have gingival
272  III,    10.  2.  1    |              php?ID=2741] (accessed on 12 February 2008).~ ~ A (2003):
273  III,    10.  2.  1    |                health status of 6- and 12-year-old schoolchildren
274  III,    10.  2.  1    |     self-esteem. Sport Science Review, 12:123-155.~ ~TNS Opinion and
275  III,    10.  2.  1    |               in Irish girls (27.3%, 9-12 years old) (ONeill et al,
276  III,    10.  2.  1    |               8.6%) and Denmark (boys: 12.5%; girls: 10.3%). These
277  III,    10.  2.  1    |              than 1 million deaths and 12 million life-years of ill
278  III,    10.  2.  1    |               adults. Obesity Research 12:1464–1472.~ ~Boros J, Németh
279  III,    10.  2.  1    |               Official Journal L 183 , 12/07/2002 P. 0051 – 0057.~[
280  III,    10.  2.  1    |            Official Journal L 404 , 30/12/2006 P. 00090025 [http://
281  III,    10.  2.  1    |            Official Journal L 404 , 30/12/2006 P. 0026 – 0038.~[http://
282  III,    10.  2.  1    |               rep_en.pdf] (accessed on 12 May 2008).~ ~Rodler I, Bíró
283  III,    10.  2.  1    |        deficiencies? Int J Nurs Pract. 12: 110-8.~ ~Chen J, Berry
284  III,    10.  2.  1    |           diseases. J Neurochem. 86: 1-12.~ ~Elmadfa I, Freisling
285  III,    10.  2.  4    |                 Am J Public Health, 86(12): 1717-1722.~ ~Kononen J,
286  III,    10.  3.  1    |            consists of a day period of 12 hours, an evening period
287  III,    10.  3.  1    |            consists of a day period of 12 hours, an evening period
288  III,    10.  3.  2    |            annual emissions from about 12 000 industrial facilities
289  III,    10.  3.  2    |          various types of phosphorus (-12%) and the emission of dioxins/
290  III,    10.  3.  2    |               round in 1987/8 included 12 European countries and indicated
291  III,    10.  3.  4    |            countries26, affecting over 12 million people, with an
292  III,    10.  3.  4    |         occurrence and effects of over 12.800 mass disasters in the
293  III,    10.  4.  1    |              and Canada (6-city study, 12-city and 24-city study)
294  III,    10.  4.  2    |            Protection Commissioner, on 12 January. 2000. The White
295  III,    10.  4.  2    |                 and came into force on 12 June 2004. In order to obtain
296  III,    10.  4.  2(29)|          Directive 92/117/EEC(OJ L 325,12.12.2003 p. 31)~
297  III,    10.  4.  2(29)|       Directive 92/117/EEC(OJ L 325,12.12.2003 p. 31)~
298  III,    10.  4.  2    |                accordance with Article 12.2 of Regulation (EC) No
299  III,    10.  4.  2    |               Directive 2006/122/EC of 12 December 2006) while the
300  III,    10.  4.  2(37)|                vegetables (OJ L 350,14.12.1986, p 71).~
301  III,    10.  4.  2    |                existing MRLsArticle 12;~· MRLs for all active substances
302  III,    10.  4.  2    |                on Persistence in Soil. 12 July 2000. 9188/VI/97. Available
303  III,    10.  4.  2    |       Parliament and of the Council of 12 March 2001 on the deliberate
304  III,    10.  4.  2    |             European Communities No. L 12/3, 18 January 2007 Available
305  III,    10.  4.  2    |              Communities No. L 183/51, 12 July 2002. Available at:~htt ~ ~
306  III,    10.  4.  2    |            Official Journal L 350 , 14/12/1990. Available at:~htt ~ ~
307  III,    10.  4.  2    |                Health Perspectives 112(12): 1204-1207~ ~Kallenborn,
308  III,    10.  4.  3    |                outbreaks resulting in >12 000 episodes of illness
309  III,    10.  5.  1    |          population across the EU is 8-12 million, mainly concentrated
310  III,    10.  5.  1    |               at different tests in 10-12 y old pupils (Wargocki and
311  III,    10.  5.  1    |        Environmental Health 15(1-2): 1-12.~Loftness V, Hakkinen B,
312  III,    10.  5.  2    |        rural settings.~ ~Figure 10.5.2.12. Infection prevalence in
313  III,    10.  5.  2    |              Services Research 2004, 4:12.~[http://www.biomedcentral.
314  III,    10.  5.  2    |          biomedcentral.com/1472-6963/4/12] (accessed on 19 September
315  III,    10.  5.  2    |           different.html] (accessed on 12 April 2007)~ ~Netherlands
316  III,    10.  5.  2    |          ruralhealth.pdf] (accessed on 12 November 2007)~ ~
317  III,    10.  5.  3    |            absence during the previous 12 months. Furthermore, perceived
318  III,    10.  5.  3    |            individuals during the past 12 month which irrespective
319  III,    10.  5.  3    |              problems at least once in 12 months (Table 10.5.3.1).
320  III,    10.  5.  3    |              Absence from work in last 12 month due to health problems~ ~
321  III,    10.  5.  3    |           million Euro for Austria and 12.6 for Belgium. In many countries,
322  III,    10.  5.  3    |              agriculture (table 10.5.3.12). A lack of job control
323  III,    10.  5.  3    |          communication.~ ~Table 10.5.3.12. Work organisational risks
324  III,    10.  5.  3    |                from 17% in Finland and 12% in the Netherlands to 3%
325  III,    10.  5.  3    |            absenteeism in the range of 12% to 36% with a return-on-investment
326  III,    10.  5.  3    |          European Journal of Neurology 12 (Supplement 1):1-27.~Ashton
327  III,    10.  5.  3    |                Directive 89/391/EEC of 12 June 1989 on the introduction
328  III,    10.  6.  1    |          network members over the last 12 months. Another dimension
329  III,    10.  6.  1    |              social support and scores 12-14 strong social support.~ ~
330   IV,    11.  1.  5    |              have hospitals stays 8 to 12 days longer than they should (
331   IV,    11.  1.  6    |                 including 8 (1%), 214 (12%), and 18 hospitals respectively).
332   IV,    11.  5.  3    |             transplantation (figure 11.12) organ exchange and organ
333   IV,    11.  5.  3    |           European countries~Figure 11.12. Organ transplantation in
334   IV,    11.  5.  3    |               events, whereas in other 12 the system is driven by
335   IV,    11.  5.  4    |                 In spite of this, only 12% of Europeans currently
336   IV,    11.  6.  2    |          Latvia). As shown in Table 11.12, the countries with predominantly
337   IV,    11.  6.  2    |            insurance funds.~ ~Table 11.12. Financing mix separated
338   IV,    11.  6.  5    |              Netherlands." Euro Health 12(2): 7-9.~ ~Belli P (2003):
339   IV,    11.  6.  5    |                Journal of Medicine 335(12): 891-894.~ ~Boyle S (2007): "
340   IV,    11.  6.  5    |             for Quality in Health Care 12(4): 281-295.~ ~Bunker J,
341   IV,    11.  6.  5    |             for Quality in Health Care 12(2): 133-42.~ ~Cheah TS (
342   IV,    11.  6.  5    |            Journal of Health Economics 12: 431-57.~ ~Cutler DM (2002): "
343   IV,    12            |                                        12. INSTITUTIONAL AND POLICY
344   IV,    12.  1        |                                        12.1. Introduction~ ~A number
345   IV,    12.  1        |        initiatives in the field (Table 12.1). Even today, public health
346   IV,    12.  1        |              State competence.~ ~Table 12.1. Healthrelated precursor
347   IV,    12.  1        |                 Article 152(1)) (Table 12.2). Whilst the Amsterdam
348   IV,    12.  1        |               is not surprising (Table 12.2).~ ~Table 12.2. EU Treaty
349   IV,    12.  1        |       surprising (Table 12.2).~ ~Table 12.2. EU Treaty Articles concerning
350   IV,    12.  1        |                billion citizens (Table 12.3). Prevention has the potential
351   IV,    12.  1        |           public expectations.~ ~Table 12.3. Some examples highlighting
352   IV,    12.  1        |               of the Treaty (see Table 12.3), related to the movement
353   IV,    12.  2        |                                        12.2. The European strategy
354   IV,    12.  2        |                 principle (see Section 12.7.), and is likely to make
355   IV,    12.  2        |              some examples, see Tables 12.4 and 12.5.~ ~Table 12.4.
356   IV,    12.  2        |          examples, see Tables 12.4 and 12.5.~ ~Table 12.4. Policies
357   IV,    12.  2        |          Tables 12.4 and 12.5.~ ~Table 12.4. Policies and control
358   IV,    12.  2        |            been officially launched on 12 June 2007 at the European
359   IV,    12.  2        |             seriously.~ ~In 2005, only 12 of the 25 (IDF Europe/FEND
360   IV,    12.  2        |         starting in 2007. ~ ~ ~ ~Table 12.5. Policies and control
361   IV,    12.  3        |                                        12.3. The reviewed European
362   IV,    12.  4        |                                        12.4. Co-ordination mechanisms
363   IV,    12.  4        |           other than D.G. SANCO (Table 12.6).~ ~Table 12.6. Health
364   IV,    12.  4        |            SANCO (Table 12.6).~ ~Table 12.6. Health across the European
365   IV,    12.  4        |            health policy makers (Table 12.7). Working as technical
366   IV,    12.  4        |             established in 2006.~Table 12.7. Community agencies directly
367   IV,    12.  4        |            health is provided in Table 12.8.~ ~ ~Table 12.8. Financial
368   IV,    12.  4        |               in Table 12.8.~ ~ ~Table 12.8. Financial community instruments
369   IV,    12.  5        |                                        12.5. The European Public Health
370   IV,    12.  5        |               on multiple lines (Table 12.9).~ ~Table 12.9. Actions
371   IV,    12.  5        |            lines (Table 12.9).~ ~Table 12.9. Actions referred to in
372   IV,    12.  5        |          collection and use (see Annex 12.1).~ ~ ~Annex 12.1. System
373   IV,    12.  5        |             see Annex 12.1).~ ~ ~Annex 12.1. System of European Community
374   IV,    12.  5        |            Jagger, in press).~ ~Figure 12.A1.1a Trend in the proportion
375   IV,    12.  5        |          Member States - men.~ ~Figure 12.A1.1b Trend in the proportion
376   IV,    12.  6        |                                        12.6. The Public Health Forum~ ~
377   IV,    12.  7        |                                        12.7. Health in all policies~ ~
378   IV,    12.  7        |             declaring success.~ ~Annex 12.2. Declaration on Health
379   IV,    12.  8        |                                        12.8. International initiatives~ ~
380   IV,    12.  8        |                27 member States (Table 12.10) started in the health
381   IV,    12.  8        |               December 2005.~ ~ ~Table 12.10. The 27 European Union
382   IV,    12.  9        |                                        12.9. The cooperation with
383   IV,    12. 10        |                                        12.10. Policy developments
384   IV,    12. 10        |              European level (see Annex 12.3). Through their priorities
385   IV,    12. 10        |             Community level (see Annex 12.3).~ ~Annex 12.3 Priorities
386   IV,    12. 10        |               see Annex 12.3).~ ~Annex 12.3 Priorities and initiatives
387   IV,    12. 10        |               States is given in Annex 12.4.~ ~Annex 12.4. Initiatives
388   IV,    12. 10        |           given in Annex 12.4.~ ~Annex 12.4. Initiatives adopted at
389   IV,    12. 10        |                1973, young people aged 12 to 25 years) and Promoting
390   IV,    12. 10        |                youth (adolescents aged 12 to 19), both conducted/coordinated
391   IV,    12. 10        |                1973, young people aged 12 to 25 years) conducted/coordinated
392   IV,    12. 10        |              health for children until 12 years is given, includes
393   IV,    12. 10        |            76017 (1-8-2002) and 82942 (12-9-2003) smoking is forbidden
394   IV,    12. 10        |                Duration: 01/07/2006-31/12/2007) ~The SAFE project,
395   IV,    12. 10        |             health~ high~Decision 1877/12/2005 National plan of action
396   IV,    13.  2.  2    |              than 1 million deaths and 12 million life-years of ill
397   IV,    13.  2.  2    |                EU accounting for about 12% of disability adjusted
398   IV,    13.  9        |                in Europe. Eur J Neurol 12 Suppl 1:1-27.~EPC (Economic